866-997-4948(US-Canada Toll Free)

Osteoporosis: Epidemiology Forecast to 2027

Published By :

GlobalData

Published Date : Apr 2018

Category :

Pharmaceutical

No. of Pages : 41 Pages

Osteoporosis: Epidemiology Forecast to 2027

Summary

Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a persons bone cells dissolve (resorption) and new bone cells grow back (formation). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture.

To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market research. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.

In the 7MM, the total prevalent cases of osteoporosis will increase from 45,617,583 cases in 2017 to 52,482,628 cases in 2027, at an Annual Growth Rate (AGR) of 1.50%. In the 7MM, the diagnosed prevalent cases of osteoporosis will increase from 21,637,066 cases in 2017 to 24,553,120 cases in 2027, at an AGR of 1.35%. GlobalData forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of osteoporosis during the forecast period.

Scope

- The Osteoporosis Epidemiology Report provides an overview of the risk factors and global trends of osteoporosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report ncludes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of osteoporosis, and total and diagnosed prevalent cases of primary osteoporosis, segmented by sex and age in these markets. In addition, this report provides a 10-year epidemiological forecast for the total and diagnosed prevalent cases of secondary osteoporosis, total and diagnosed prevalent cases of osteopenia, segmented by sex. The report also includes the total and diagnosed prevalent cases of type 1 (postmenopausal) osteoporosis, and the total and diagnosed prevalent cases of type 2 (age-associated/ senile) osteoporosis, and total and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.
- The osteoporosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Osteoporosis Epidemiology report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global osteoporosis market.
- Quantify patient populations in the global osteoporosis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for osteoporosis therapeutics in each of the markets covered.
- Understand magnitude of osteoporosis types in each market.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Osteoporosis: Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 9
3.3 Global and Historical Trends 10
3.4 Forecast Methodology 11
3.4.1 Sources 11
3.4.2 Forecast Assumptions and Methods 15
3.5 Epidemiological Forecast for Osteoporosis (2017-2027) 22
3.5.1 Total Prevalent Cases of Osteoporosis 22
3.5.2 Age-Specific Total Prevalent Cases of Osteoporosis 24
3.5.3 Sex-Specific Total Prevalent Cases of Osteoporosis 25
3.5.4 Total Prevalent Cases of Osteoporosis by Primary and Secondary Osteoporosis 25
3.5.5 Total Prevalent Cases of Primary Osteoporosis by Type 26
3.5.6 Total Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use 27
3.5.7 Diagnosed Prevalent Cases of Osteoporosis 28
3.5.8 Age-Specific Diagnosed Prevalent Cases of Osteoporosis 29
3.5.9 Sex-Specific Diagnosed Prevalent Cases of Osteoporosis 30
3.5.10 Diagnosed Prevalent Cases of Osteoporosis by Primary and Secondary Osteoporosis 30
3.5.11 Diagnosed Prevalent Cases of Primary Osteoporosis by Type 31
3.5.12 Diagnosed Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use 32
3.5.13 Total Prevalent Cases and Diagnosed Prevalent Cases of Osteopenia 33
3.6 Discussion 33
3.6.1 Epidemiological Forecast Insight 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 34
4 Appendix 35
4.1 Bibliography 35
4.2 High-Prescribing Physician Survey 38
4.3 About the Authors 39
4.3.1 Epidemiologist 39
4.3.2 Reviewers 39
4.3.3 Global Director of Therapy Analysis and Epidemiology 40
4.3.4 Global Head and EVP of Healthcare Operations and Strategy 40
4.4 About GlobalData 41
4.5 Contact Us 41
4.6 Disclaimer 41

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Osteoporosis 9
Table 2: 7MM Total Prevalent Cases of Osteoporosis by Primary Osteoporosis and Secondary Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 26
Table 3: 7MM, Total Prevalent Cases of Primary Osteoporosis by Type, Ages 30 Years, N, 2017 26
Table 4: 7MM Diagnosed Prevalent Cases of Osteoporosis by Primary Osteoporosis and Secondary Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 31
Table 5: 7MM, Diagnosed Prevalent Cases of Primary Osteoporosis by Type, Ages 30 Years, N, 2017 31
Table 6: 7MM Total Prevalent Cases and Diagnosed Prevalent Cases of Osteopenia, Both Sexes, Ages 30 Years, N, 2017 33
Table 7: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2017 38

1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, 2017 and 2027 5
Figure 2: 7MM, Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, 2017 and 2027 6
Figure 3: 7MM, Age-Standardized Total Prevalence of Osteoporosis, Men and Women, Ages 30 Years, 2017 10
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Osteoporosis, Men and Women, Ages 30 Years, 2017 11
Figure 5: 7MM, Sources Used and Not Used to Forecast Total Prevalent Cases of Osteoporosis 12
Figure 6: 7MM, Sources Used to Forecast Total Prevalent Cases and Diagnosed Prevalent Cases of Primary and Secondary 13
Figure 7: 7MM, Sources Used to Forecast Total Prevalent Cases of Osteopenia 13
Figure 8: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of Osteoporosis 14
Figure 9: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of Osteopenia 14
Figure 10: 7MM, Total Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 23
Figure 11: 7MM, Age-Specific Total Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 24
Figure 12: 7MM, Sex-Specific Total Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 25
Figure 13: 7MM, Total Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use, Both Sexes, Ages 30 Years, N, 2017 27
Figure 14: 7MM, Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 28
Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 29
Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages 30 Years, N, 2017 30
Figure 17: 7MM, Diagnosed Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use, Both Sexes, Ages 30 Years, N, 2017 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *